1. Belgium Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Ion Beam Applications S.A.

Ion Beam Applications S.A.

IOBCF
Ion Beam Applications S.A.US flagOther OTC
19.10
USD
- -
- -
560.17MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
7.93
8.07
9.6
11.44
8.11
8.78
9.59
10.53
10.64
12.4
15.99
17.03
21.15
Basic EPS, GAAP
-0.04
0.89
2.17
0.85
-1.34
-0.15
0.26
1.08
0.13
0.21
-0.31
0.32
0.43
Free Cash Flow per Basic Share
0.11
0.37
1.46
-1.04
-2.05
-1.27
1.48
3.25
2.79
0.49
-1.1
-0.62
-1.31
Dividend per Share
- -
0.01
0.19
1.4
0.28
- -
- -
0.08
0.2
0.19
0.21
0.17
0.24
Book Value per Share
1.55
2.44
4.44
3.83
2.16
1.96
2.21
3.18
3.18
3.22
2.69
2.8
2.92
Tangible Book Value per Share
2.03
3.46
5.37
4.75
3.17
3.22
3.44
4.51
4.02
3.37
2.84
2.91
2.87
Basic Weighted Avg Shares
27
27
28
29
29
29
29
30
29
29
29
29
29
Sales/Revenue/Turnover
213
221
270
329
236
257
283
312
313
361
467
498
620
Operating Margin (%)
2.27
10.15
8.83
9.59
-7.71
1.9
0.66
12.9
4.37
1.37
1.15
1.99
3.58
Depreciation Expense
5
4
4
5
6
7
12
12
10
11
12
12
14
Net Income, GAAP
-1
24
61
24
-39
-4
8
32
4
6
-9
9
13
Effective Tax Rate (%)
- -
- -
6.03
12.04
- -
- -
29.31
3.43
53.01
- -
- -
37.88
32.17
Profit Margin (%)
-0.48
11.01
22.63
7.43
-16.58
-1.71
2.69
10.23
1.24
1.68
-1.95
1.86
2.05
Working Capital
27
46
118
110
69
83
76
137
79
39
-1
-21
-3
LT Debt
42
27
15
28
19
54
59
66
54
31
29
26
78
Total Equity
67
108
164
150
109
103
111
142
126
116
106
111
127
Return on Invested Capital (%)
- -
- -
13.63
15
- -
- -
0.69
19.12
3.04
- -
- -
4.13
7.76
Return on Capital (%)
- -
- -
48.95
17.18
- -
- -
6.47
22.14
2.95
- -
- -
8.63
9.42
Return on Common Equity (%)
-2.41
44.9
63.82
20.78
-45.28
-7.31
12.44
40.11
4.13
6.46
-10.56
11.53
15.2

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.4%
-1.69%
14.65%
Free Cash Flow
-55.72%
-70.23%
113.05%
Net Income, GAAP
-80.88%
-89.22%
37.59%
Sales/Revenue/Turnover
9.87%
15.23%
24.49%
Total Cash Common Dividend
- -
37.41%
44.36%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
467
2024
- -
- -
- -
- -
498
2025
- -
- -
- -
- -
620

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.31
2024
- -
- -
- -
- -
0.32
2025
- -
- -
- -
- -
0.43

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.21
2024
- -
- -
- -
- -
0.17
2025
- -
- -
- -
- -
0.24

Company Description

APIChatGPT
CEO
Olivier Legrain
Full Time Employees
2,302
Sector
Healthcare
Industry
Medical - Devices
Address
3, Chemin du Cyclotron Louvain-la-Neuve BU Belgium 1348
IPO Date
Sep 24, 2001
Website
iba-worldwide.com
Similar Companies
Profusa, Inc. Common Stock (PFSA)
CLASSYS Inc. (214150.KQ)
Nuwellis, Inc. (NUWE)
Drägerwerk AG & Co. KGaA (DWRKF)
Luxbright AB (publ) (LXB.ST)
Misonix, Inc. (MSON)
Business
Ion Beam Applications SA (IBA) develops, manufactures and markets particle accelerator-based solutions for proton therapy, dosimetry, radiopharma solutions and industrial applications including sterilization; core offerings encompass ProteusONE and ProteusPLUS proton therapy systems, cyclotron technologies such as Cyclone ICON and Cyclone Cube for radioisotope production, radiochemistry modules, dosimetry tools like myQA Blue Phantom for radiation therapy and medical imaging quality assurance, QUASAR anthropomorphic phantoms, and Beyond electron beam systems for industrial processing. Founded in 1986 and headquartered in Louvain-la-Neuve, Belgium, the company operates worldwide with approximately 2,100 employees across more than 40 locations, serving healthcare providers, pharmaceutical firms and industrial clients in regions including Europe, the United States, Asia-Pacific and China. Recent developments include the acquisition of Phantomics in October 2025 to enhance medical imaging QA capabilities, a memorandum of understanding with Varian signed at ASTRO 2025 for proton therapy interoperability and co-development of technologies like DynamicARC and FLASH therapy support, the inauguration of its Asia-Pacific headquarters in Beijing in late 2025 to bolster regional manufacturing, innovation and customer service, closure of a EUR125 million refinancing club deal with major banks plus a EUR10 million subordinated loan from Wallonie Entreprendre, groundbreaking for the PanTera commercial-scale Actinium-225 production facility, and strong order intake with four ProteusONE systems sold in Q3 2025.

Company News

APIChatGPT

  • defenseworld.net

    Ion Beam Applications (OTCMKTS:IOBCF) Trading Up 5.3% – Here’s What Happened

  • seekingalpha.com

    Ion Beam Applications SA (IOBCF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Ion Beam Applications SA (IOBCF) Q3 2025 Earnings Call Transcript

  • seekingalpha.com

    Ion Beam Applications SA (IOBCF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    Ion Beam Applications SA (IOBCF) Q2 2024 Earnings Call Transcript

  • seekingalpha.com

    Ion Beam Applications SA (IOBCF) Q4 2023 Earnings Call Transcript

  • seekingalpha.com

    Ion Beam Applications SA (IOBCF) Q4 2022 Earnings Call Transcript

  • seekingalpha.com

    Ion Beam Applications SA (IOBCF) Q2 2022 Earnings Call Transcript